Camelid V H H affinity ligands enable separation of closely related biopharmaceuticals

• Published in: Biotechnology journal Vol. 12; no. 2
• Main Authors: Pabst, Timothy M, Wendeler, Michaela, Wang, Xiangyang, Bezemer, Sandra, Hermans, Pim, Hunter, Alan K
• Format: Journal Article
• Language: English
• Published: Germany 01.02.2017
• Subjects: Antibodies - isolation & purification; Bacterial Toxins - isolation & purification; Chromatography, Affinity - methods; Exotoxins - isolation & purification; Prothrombin - isolation & purification; Moxetumomab pasudotox; Prothrombin; Conformational epitopes; Affinity chromatography; VHH ligand
• DOI: 10.1002/biot.201600357

Interest in new and diverse classes of molecules such as recombinant toxins, enzymes, and blood factors continues to grow for use a biotherapeutics. Compared to monoclonal antibodies, these novel drugs typically lack a commercially available affinity chromatography option, which leads to greater process complexity, longer development timelines, and poor platformability. To date, for both monoclonal antibodies and novel molecules, affinity chromatography has been mostly reserved for separation of process-related impurities such as host cell proteins and DNA. Reports of affinity purification of closely related product variants and modified forms are much rarer. In this work we describe custom affinity chromatography development using camelid V H antibody fragments as "tunable" immunoaffinity ligands for separation of product-related impurities. One example demonstrates high selectivity for a recombinant immunotoxin where no binding was observed for an undesired deamidated species. Also discussed is affinity purification of a coagulation factor through specific recognition of the gamma-carboxylglutamic acid domain.